Last updated: July 22, 2026
Hydrocodone Bitartrate and Pseudoephedrine Hydrochloride Investment Scenario and Patent/Regulatory Fundamentals
Hydrocodone bitartrate and pseudoephedrine hydrochloride (combination opioid plus decongestant) is a controlled product with U.S. approval history concentrated in older fixed-dose formulations. Investment fundamentals are driven by (1) schedule and REMS-like compliance posture, (2) DEA diversion-control friction, (3) the patent and exclusivity footprint for the specific marketed dosage forms, and (4) whether a shelf-stable generic pipeline exists that can access the commercial channel. For investors, the dominant value question is whether any “last-mile” formulation or method-of-use protection still blocks generic entry for the exact strengths and dosage forms tied to current sales.
No complete, investment-grade valuation package (patent-by-patent expiry map tied to exact FDA label, Orange Book coverage, AND current litigation status) can be produced from the information available in this prompt.
What is the U.S. FDA status of hydrocodone bitartrate plus pseudoephedrine hydrochloride?
Featured snippet answer: The combination is an older U.S.-approved fixed-dose product line. For current commercial freedom-to-operate and launch timing, the governing dataset is the drug’s specific NDA/ANDA Orange Book listing(s) by strength and dosage form, plus any listed patents and exclusivity tied to those listings.
What label and dosage-form specifics determine investment exposure?
Investment outcomes hinge on granularity:
- Strengths (mg hydrocodone base equivalents and mg pseudoephedrine salt equivalent)
- Dosage form (tablet/capsule formulation class)
- Intended use language in the label
- Whether the marketed product matches the patent-protected formulation claims (often composition, process, or formulation-stability claims)
What regulatory posture matters for controlled combinations?
- Hydrocodone is a Schedule II opioid.
- Pseudoephedrine is regulated under chemical control and retail dispensing controls; manufacturing and distribution face heightened compliance.
- Fixed-dose combination products typically experience higher compliance, monitoring, and distribution friction than non-controlled/non-regulated products.
What patents protect hydrocodone bitartrate and pseudoephedrine hydrochloride combinations?
Featured snippet answer: The protected subject matter is typically captured in Orange Book-listed patents for the specific NDA, including formulation/composition patents, manufacturing-process patents, and sometimes method-of-use patents. The actual answer depends on the exact marketed NDA and dosage strength.
How to structure a patent estate for this drug (for diligence)
A practical patent map for investment must include:
- Composition of matter (active ingredient combinations and salt forms, if claimed)
- Formulation patents (excipients, film coatings, sustained-release technologies, absorption-rate modifiers)
- Manufacturing/process patents (granulation, blending, tableting parameters, stability controls)
- Method-of-use patents (if any are listed for indications or dosing regimens)
- Patent term adjustments and exclusivity additions (if tied to the NDA)
How many patents cover the combination and for which dosage strengths?
This cannot be determined accurately without Orange Book listing data for the exact NDA(s) and strengths. A credible investment memo must tabulate each listed patent number, expiration date, and linkage to the covered drug product.
When does hydrocodone bitartrate and pseudoephedrine lose exclusivity?
Featured snippet answer: Exclusivity timing is driven by the NDA’s exclusivity periods (new chemical entity, new clinical investigation, pediatric, orphan, etc., if applicable) plus patent expiry and any PTA. Precise dates require the Orange Book exclusivity and patent timeline for the linked NDA/strength.
How investors should interpret “loss of exclusivity”
For older combination products, “exclusivity” often matters less than:
- Patent block status for key listed patents
- Whether generic applicants can carve around or successfully challenge listed patents
- Whether settlements constrain launch timing beyond patent expiry
What generic entry risks exist for hydrocodone bitartrate and pseudoephedrine hydrochloride?
Featured snippet answer: Generic entry risk is dominated by whether any Orange Book-listed patents still block ANDA approval for the exact strength/dosage form, and whether Paragraph IV challenges have already been litigated or settled.
Paragraph IV challenge scenarios that drive investment timing
Investment-relevant cases typically fall into:
- No remaining unexpired blocking patents for the marketed strengths (generic entry likely)
- One or more remaining blocking patents with ongoing IV litigation (delayed entry and upside for the brand)
- IV challenges settled with a non- or limited-entry date (predictable but negotiated launch constraints)
What patent litigation affects hydrocodone bitartrate and pseudoephedrine?
Featured snippet answer: Litigation affects launch timing only when it ties to specific Orange Book blocking patents linked to the marketed NDA. Without case identifiers, district court records, and settlement dates tied to the correct NDA/strength, no defensible litigation impact assessment can be produced.
What to pull into a diligence pack
- Case caption and court for each relevant IV ANDA
- Asserted patent numbers and claims
- Status: filed, stayed, decided, appeal, or settlement
- Settlement terms: launch date carve-outs, licensing, supply commitments, exclusivity buybacks
- Injunction status or carve-out triggers
What is the Orange Book status of hydrocodone bitartrate and pseudoephedrine hydrochloride?
Featured snippet answer: Orange Book status is defined by the NDA number(s) and the set of listed patents for each strength/dosage form. The investment conclusion hinges on how many patents remain unexpired and which are “blocking” under FDA 21 C.F.R. rules.
How to translate Orange Book data into an investor view
A bankable framework is:
- For each strength: list patents, expiration date, patent type, and whether listed as “drug product” or “method of use”
- Identify the earliest patent expiry date
- Identify whether any patents extend beyond that due to continuations, PTA, or pediatric exclusivity
- Overlay known IV litigation and settlement outcomes
How does hydrocodone bitartrate plus pseudoephedrine compare with other hydrocodone combination opioids?
Featured snippet answer: Comparison is mostly about (1) how many patent-protected product line variants remain, (2) how aggressively IV challenges have progressed, and (3) compliance and distribution friction by formulation and schedule category. Without a competitor table of Orange Book entries, no quantified comparison can be provided.
Investment-relevant comparables
- Other hydrocodone combination products with different decongestant actives or sustained-release technologies
- Standalone hydrocodone products that share manufacturing and distribution channels
- Non-opioid alternatives for upper respiratory symptom relief (commercial substitution risk)
What formulations are protected by patents for hydrocodone bitartrate and pseudoephedrine?
Featured snippet answer: Formulation protection is usually tied to the manufacturing/process route and dosage-form design for specific immediate-release versus extended-release behavior. The correct answer requires mapping claimed formulations to the Orange Book patent list and the FDA label for each dosage form.
Common formulation patent buckets for these products
- Tablets/capsules with specific excipient systems that control dissolution
- Granulation and compression processes for uniformity
- Film coating systems that affect release
- Stability patents targeting moisture/temperature sensitivities
Which companies are challenging patents on this combination?
Featured snippet answer: Patent challengers are identified by ANDA filings and Paragraph IV notices naming the listed patents. Without the Orange Book patent list and IV notice history for the specific NDA(s), no accurate company list can be produced.
What commercial fundamentals drive revenue exposure for this drug?
Featured snippet answer: Revenue exposure depends on controlled-substance demand dynamics, pharmacy dispensing patterns, payer coverage, and how quickly generic competitors can obtain ANDA approvals for the exact strengths.
Key value drivers
- Net sales volume trends, by strength
- Channel access: wholesaler distribution and retail availability
- Pricing pressure: brand discounting vs generic list price spreads
- Compliance burden and disruption risk (DEA/DDD-level enforcement sensitivity)
Key downside drivers
- Accelerated generic substitution when blocking patents are removed
- Supply chain disruptions due to controlled chemical handling
- Litigation and regulatory scrutiny that affects access and distribution
How strong is the patent estate for hydrocodone bitartrate and pseudoephedrine?
Featured snippet answer: Patent estate strength is measured by unexpired blocking patents on the current marketed strengths, the defensibility of asserted claims, and the probability of generic workarounds via carve-outs or design-around.
Investment-grade scoring model (what diligence should quantify)
- Patent count by category (composition, formulation, process, method-of-use)
- Remaining term weighted by probability of blocking generic approvals
- Litigation history: win-loss rates for the patent holder
- Whether patents are narrow (easy design-around) or broad (hard to circumvent)
What manufacturing and IP barriers could delay generics for this combination?
Featured snippet answer: Barriers typically come from formulation/process claims and from controlled-substance compliance. The magnitude varies by whether the patents target critical manufacturing parameters or only ancillary aspects.
Where generic supply tends to fail in diligence
- Achieving dissolution and bioavailability targets consistent with the reference product
- Replicating stability under controlled humidity and temperature ranges
- Documenting process consistency for cGMP and validation at commercial scale
- Controlled substance licensure and distributor onboarding timelines
Key Takeaways
- Investment success for hydrocodone bitartrate plus pseudoephedrine hinges on Orange Book-linked patent status by exact strength and dosage form, not on the general drug category.
- The dominant timeline variable is the expiry of blocking patents and any Paragraph IV litigation or settlement outcomes tied to the specific NDA.
- Commercial exposure is amplified by controlled-substance and chemical-control compliance, which can raise execution risk for both incumbents and challengers.
- Without the Orange Book NDA/patent-by-strength dataset and current litigation/settlement records for the marketed product line, no defensible patent- and exclusivity-based valuation can be produced for this specific combination.
FAQs
- How do Paragraph IV challenges change the generic launch date for hydrocodone decongestant combinations?
- What Orange Book patent categories most often block ANDA approval for opioid/decongestant fixed-dose products?
- Do settlement agreements typically include supply or launch carve-outs for hydrocodone combination drugs?
- How does controlled-substance handling affect manufacturing timelines for generic hydrocodone products?
- What are the main formulation differences that determine whether a generic can be considered equivalent to the reference hydrocodone/pseudoephedrine product?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- U.S. Food and Drug Administration. Drug Approval Process: ANDA and Paragraph IV Certifications guidance materials.
- FDA. Approved Drug Products databases for hydrocodone bitartrate/pseudoephedrine hydrochloride combination listings (NDA-linked label and regulatory milestones).
